Combatting chemoresistance in GBM

Combatting chemoresistance in GBM
By using a combinational therapeutic strategy, a research team have created a promising approach to combat chemoresistance in GBM. Glioblastoma often resists front-line chemotherapies, including temozolomide, a drug that damages DNA and triggers tumour cell death. Nearly half of glioblastoma patients resist the treatment by producing a DNA-repairing enzyme, MGMT, but until recently it wasn’t clear why temozolomide wasn’t working for patients who lacked the MGMT enzyme. Using glioblast...

Comments

Popular posts from this blog

Grand Connection Supports Small Businesses Impacted by Pandemic.

Advance information: World premiere of the QUANTRON QARGO 4 EV in the light truck segment at QUANTRON Q-Days from April 26-28, 2022

BYTON Plant Open Day: reaffirming start of series production by end of 2019